Drug Database
ES

escitalopram + clonazepam (Citapure Forte)

✓ Approved

A. N. Pharmacia Laboratories · GABRA1 · Small Molecule

What is escitalopram + clonazepam?

escitalopram + clonazepam is a small molecule developed by A. N. Pharmacia Laboratories. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesCitapure Forte
CompanyA. N. Pharmacia Laboratories
Drug ClassSmall Molecule
Molecular TargetGABRA1, GABRA2, GABRA3, GABRA4, SLC6A4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, A. N. Pharmacia Laboratories

Mechanism of Action

Molecular Targets

escitalopram + clonazepam acts on 5 molecular targets:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (ECA4, EJM)
GABRA2gamma-aminobutyric acid type A receptor alpha2 subunit (EIEE78, DEE78)
GABRA3gamma-aminobutyric acid type A receptor alpha3 subunit (EPILX2)
GABRA4gamma-aminobutyric acid type A receptor alpha4 subunit ()
SLC6A4solute carrier family 6 member 4 (SERT1, 5-HTTLPR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

escitalopram + clonazepam is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersBipolar I disorder✓ Approved
Psychiatric disordersGeneralised anxiety disorder✓ Approved

Related Research Articles

PubMedDepression and anxiety2026-11-12

No Significant Differences in Antidepressant Remission and Response Rates Between Anxious and Nonanxious Depression: A Multicenter Study in Taiwan.

Lee Wei-Yang WY, Tsou Hsiao-Hui HH, Chu Si-Yu SY, Hsu Ya-Ting YT et al.

Anxious depression, defined by coexisting anxiety and depressive symptoms, has been associated with poorer treatment outcomes, though findings remain inconsistent. This study examined whether anxious depression influences antidepressant efficacy in an Asian population. This multicenter, single-blind study across five hospitals was conducted in Taiwan from May 2006 to December 2009. Patients aged 18 and older with major depressive disorder (MDD) were diagnosed and treated with either escitalopram or paroxetine. The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory-II (BDI-II) assessed outcomes. Anxious depression was defined as a HAM-D anxiety factor score ≥ 7. We assessed treatment efficacy by remission and response rates, as well as changes in depression scores. The study included 302 patients, of whom 193 were classified as having anxious depression and 109 as having nonanxious depression. No significant differences were observed in treatment dosage or duration between the anxious and nonanxious depression groups. HAM-D-defined remission rates were 40.4% and 43.1%, respectively (adjusted OR = 0.9, 95% CI = 0.6-1.5, and p = 0.651), and response rates were 62.2% and 56.9% (adjusted OR = 1.2, 95% CI = 0.7-1.9, and p = 0.517). The anxious depression group showed a greater reduction in HAM-D scores (-13.0 vs. -10.4; adjusted mean difference = -1.9, 95% CI = -3.5 to -0.4, and p = 0.014), whereas the percentage change did not differ significantly between groups (adjusted p = 0.529). BDI-II outcomes likewise showed no significant between-group differences. Time to remission (log-rank p = 0.599) and response (log-rank p = 0.264) also did not differ significantly. In this Taiwanese multicenter outpatient cohort, anxious depression was not significantly associated with lower remission or response rates during 8 weeks of treatment with escitalopram or paroxetine. These findings contribute to the limited evidence on antidepressant outcomes among Asian outpatients with anxious depression. However, the absence of statistically significant differences should not be interpreted as evidence of equivalence, and further prospective studies with larger and better-balanced samples are needed to confirm these findings. Trial Registration: ClinicalTrials.gov identifier: NCT00384020.

PMID 43017290
Read full article →
PubMedMedicine2026-11-11

Opsoclonus-myoclonus-ataxia syndrome in an elderly female: A video-based case report and literature review.

Meng Chi C, Li Yan Y, Wen Siyuan S, Chen Feifei F et al.

Opsoclonus-myoclonus-ataxia syndrome (OMAS) is rare in adults. Here, we report a rare case of OMAS in an elderly patient, accompanied by video documentation and a comprehensive literature review, which may offer valuable insights into the clinical features, diagnosis, and management of this condition. An 81-year-old female was admitted with limb tremors lasting for 1 day. During the hospitalization, she developed opsoclonus, myoclonus, ataxia, behavioral changes, and sleep disturbances. Laboratory and imaging findings were unremarkable, with no tumor detected during follow-up, supporting a diagnosis of idiopathic OMAS. Immunotherapy consisted of steroids, while symptomatic treatment included clonazepam and gabapentin. The patient showed marked symptomatic improvement after immunotherapy. At two-year follow-up, there was no evidence of recurrence or malignancy. In elderly patients, OMAS is extremely rare and often diagnosed and treated late. Comprehensive screening for malignancies and infectious triggers is critical. Early recognition and prompt immunotherapy improve outcomes.

PMID 43012765
Read full article →
PubMedClinical practice and cases in emergency medicine2026-11-11

Polysubstance-Induced Vasoplegia Managed with Venoarterial Extracorporeal Membrane Oxygenation: A Case Report.

Bleifuss William J WJ, Robinson Aaron E AE, Heather Beth M BM, Brown Hannah M HM et al.

While the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) becomes increasingly commonplace in overdose, questions about its role in various shock states remain. The application of VA-ECMO with impaired myocardial function is well established, and use in cardiogenic shock precipitated by poisoning has continued to increase. In poison-induced vasoplegia with preserved myocardial function, the role of VA-ECMO remains undefined. Many atypical antipsychotic and antidepressant agents are known to cause mild hypotension via alpha-1 adrenergic blockade. Intravenous fluids and vasopressors alone are generally effective for single-substance ingestions. In the setting of polysubstance intoxication, synergism leading to bradycardia and refractory vasoplegia refractory to conventional therapies may result, prompting consideration for extracorporeal support. A 71-year-old woman presented to the emergency department (ED) after being found obtunded near bottles of quetiapine, olanzapine, trazodone, mirtazapine, levomilnacipran, eszopiclone, and clonazepam. She underwent prehospital intubation and received push-dose epinephrine for hypotension. In the ED, the patient remained hypotensive with a relative bradycardia, requiring escalating doses of norepinephrine, vasopressin, epinephrine, angiotensin II, and methylene blue infusions. Her extremities remained warm, and point-of-care echocardiography revealed hyperdynamic function, consistent with vasoplegic shock. She subsequently underwent VA-ECMO cannulation, which was followed by a rapid decrease in vasopressor requirements and decannulation on hospital day 3. The patient recovered and was transferred to inpatient psychiatry neurologically intact. Urine mass-spectrometry revealed large peaks for quetiapine, olanzapine, milnacipran, mirtazapine, trazodone, and zopiclone. While overdose data are limited, levomilnacipran may precipitate or potentiate relative bradycardia with hypotension and a preserved ejection fraction. Significant ingestions and synergism with other agents causing peripheral alpha-1 antagonism may lead to hemodynamic instability refractory to conventional therapies. Extracorporeal life support may aid in recovery.

PMID 43014364
Read full article →
PubMedThe lancet. Psychiatry2026-11-11

Comparative efficacy and tolerability of pharmacological interventions for the acute treatment of obsessive-compulsive disorder across the lifespan: a systematic review and network meta-analysis.

Cohen Sem S, Ostinelli Edoardo E, Takamiya Akihiro A, Storosum Bram B et al.

Pharmacological treatment is recommended for obsessive-compulsive disorder. Several options are available, yet little is known on comparative effects of individual medications. We aimed to elucidate the efficacy and tolerability of pharmacotherapy for people with obsessive-compulsive disorder, across the lifespan. We did a systematic review and network meta-analysis comparing short-term pharmacological interventions for obsessive-compulsive disorder. We searched multiple databases, including MEDLINE, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials, for literature on licensed or recommended pharmacological treatments for obsessive-compulsive disorder, without age restrictions, from database inception up to March 11, 2026. We included double-blind, randomised controlled trials with outcomes between 8 and 16 weeks. Two reviewers independently and in duplicate extracted outcomes, with a quality check done by a third reviewer. Primary outcomes were efficacy, defined as change from baseline score, and tolerability, defined as the proportion of participants discontinuing treatment due to adverse events. Separately for children and adolescents (aged 0-17 years) and adults (aged ≥18 years), we calculated standardised mean differences (SMDs) and odds ratios (ORs) with random-effects pairwise and network meta-analysis. The certainty of evidence was assessed using the Confidence in Network Meta-Analysis (CINeMA) framework. People with lived experience of obsessive-compulsive disorder were involved in the entire review process, including protocol development, writing, and interpretation of the findings. The study was preregistered in Open Science Framework (identifier 4V3GS). We included 52 randomised controlled trials with 7316 participants. Nine trials were included for children and adolescents (N=822; median age 12·5 years [IQR 11·6-13·2]; 352 [55%] male and 285 [45%] female among 637 participants with reported sex distribution). 43 trials were included for adults (N=6494; median age 36·4 years [35·0-37·9]; 3105 [49%] male and 3200 [51%] female among 6305 participants with reported sex distribution). Data on ethnicity were reported in 15 (29%) of 52 randomised controlled trials, using inconsistent definitions. In children and adolescents, clomipramine was more efficacious than placebo (SMD -1·19, 95% CI -1·73 to -0·64, CINeMA low), as were sertraline (-0·52, -0·80 to -0·02, low), fluoxetine (-0·43, -0·76 to -0·10, low), and fluvoxamine (-0·39, -0·71 to -0·07, low). Clomipramine was more efficacious than fluoxetine (SMD -0·75, 95% CI -1·39 to -0·11; very low), fluvoxamine (-0·79, -1·43 to -0·16; very low), paroxetine (-0·87, -1·51 to -0·22; very low), and sertraline (-0·87, -1·51 to -0·22; very low). Only sertraline was less tolerable than placebo (OR 4·51, 95% CI 1·36 to 14·96; low). In adults, clomipramine (SMD -0·71, 95% CI -0·88 to -0·54; high), fluvoxamine (-0·63, -0·83 to -0·43; high), paroxetine (-0·51, -0·73 to -0·29; moderate), sertraline (-0·49, -0·70 to -0·28; moderate), escitalopram (-0·43, -0·85 to -0·02; moderate), and fluoxetine (-0·37, -0·6 to -0·08; moderate) were more efficacious than placebo, and clomipramine was more efficacious than fluoxetine (-0·34, -0·65 to -0·04; low). Clomipramine (OR 4·65, 95% CI 3·27 to 6·60; moderate), fluvoxamine (2·73, 1·77 to 4·20; moderate), fluoxetine (2·52, 1·27 to 4·98; moderate), sertraline (2·23, 1·49 to 3·34; moderate), and paroxetine (1·99, 1·36 to 2·93; moderate) were less tolerable than placebo. Clomipramine was less tolerable than all active comparators (OR range 1·70 to 3·50; moderate) except fluoxetine (moderate) and venlafaxine (low). Clomipramine showed the largest estimated efficacy for obsessive-compulsive disorder but had a lower tolerability than SSRIs. The evidence of its superiority over individual SSRIs was more pronounced in children and adolescents. Our findings suggest that the trade-off between efficacy and tolerability should be discussed within an individualised, shared, decision-making framework. None.

PMID 43014332
Read full article →
PubMedThe lancet. Psychiatry2026-11-10

Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depressive disorder: a systematic review and network meta-analysis.

van Haaren Paul C F PCF, van Gaalen Jakob M JM, Ostinelli Edoardo G EG, Shinohara Kiyomi K et al.

Major depressive disorder carries high risks of relapse and chronicity, necessitating treatments that achieve and maintain response (sustained response). This study aimed to compare antidepressants on their ability to achieve sustained response, and on acceptability, by synthesising data from randomised controlled trials. For this systematic review and network meta-analysis, we searched the Cochrane Register, AMED, CINAHL, Embase, LILACS, MEDLINE, MEDLINE In-Progress, PsycINFO, the UK National Research Register, and regulatory agency websites from inception to March 27, 2026. We included double-blind randomised controlled trials that compared any of 21 antidepressants head-to-head or with placebo for long-term treatment (>12 weeks) of adult unipolar major depressive disorder. We included enrichment, non-enrichment, continuation, and continuation-extension designs, and extracted study-level data. We could not derive the sex or gender distribution of participants other than female and did not extract data on race or ethnicity. Primary outcomes were efficacy (sustained response rate) and acceptability (all-cause discontinuation). We synthesised data in random-effects pairwise and network meta-analyses to estimate pooled odds ratios (ORs), using fluoxetine as a reference in the ranked forest plots. The primary analysis included head-to-head continuation and continuation-extension design studies. Enrichment design studies were incorporated in the analysis using a chain-of-evidence approach. Risk-of-bias assessment was done using the Cochrane Risk of Bias 2 tool. No people with lived experience were involved in the design, conduct, or interpretation of this study. From 54 231 records, 115 studies (30 428 participants; mean age 45·3 years [SD 8·5], 20 066 [66%] female) were included. In head-to-head continuation and continuation-extension design studies (35 studies; n=9888), sustained response differed across antidepressants. Escitalopram (OR 1·62, 95% CI 1·21-2·18), duloxetine (OR 1·57, 1·08-2·26), and agomelatine (OR 1·40, 1·06-1·85) showed higher sustained response rates than fluoxetine. Bupropion and reboxetine showed lower sustained response rates against four other antidepressants in the league table of pairwise comparisons. Escitalopram (OR 0·60, 0·43-0·83) and duloxetine (OR 0·64, 0·44-0·95) demonstrated lower all-cause discontinuation compared with fluoxetine, while reboxetine and milnacipran showed higher all-cause discontinuation against six and four other antidepressants, respectively, in the league table of pairwise comparisons. Sensitivity analyses incorporating enrichment-design studies corroborated these results. However, the certainty of evidence of the network meta-analysis results and the risk of bias in the included studies (19 [54%] of 35 had high risk of bias) might limit the reliability of the current findings. Antidepressants can differ in their efficacy for achieving sustained response and in their acceptability. These findings can inform the shared decision making for patients, prescribers, and carers in real-world practice. However, more head-to-head comparative studies are needed to provide reliable information about long-term effects of all licensed antidepressants. None.

PMID 43008763
Read full article →
PubMedmedRxiv : the preprint server for health sciences2026-11-08

Mindfulness-Based Stress Reduction for Generalized Anxiety Disorder: Systematic Review and Meta-Analysis.

Neves Vinicius V VV, Larbi Nana Amma O O NAOO, Acabchuk Rebecca L RL, Haygood Laura N LN et al.

To evaluate the efficacy and safety of Mindfulness-Based Stress Reduction (MBSR) for anxiety symptoms in adults with generalized anxiety disorder (GAD). Systematic review and meta-analysis. CINAHL, Embase, MEDLINE, PsycINFO, Scopus, SocINDEX, ERIC (EBSCO), and ProQuest Dissertations & Theses Global were searched from inception to October 2025; identified trial protocols were hand-searched for subsequent reports through February 2026. Randomized, non-randomized, and single-arm trials evaluating the effects of MBSR on anxiety in adults with GAD. Two authors independently screened records, extracted data, and assessed risk of bias. The primary outcome was anxiety symptoms; the secondary outcome was adverse events. Random-effects meta-analyses were conducted, and certainty of evidence was assessed. Of 19 included reports (16 independent samples), 8 randomized controlled trials ( n =1,012) were included in the primary meta-analysis. MBSR significantly reduced anxiety symptoms vs. waitlist (Hedges' g =-0.88; 95% CI -1.57 to -0.19) and general active comparators ( g =-0.85; 95% CI -1.15 to -0.54), and showed no significant difference vs. escitalopram in two linked trials ( g =0.09; 95% CI -0.11 to 0.29), with fewer adverse events in the in-person trial, the only one reporting them (15% vs. 79%; number needed to treat to avoid harm=2). GRADE certainty of evidence was high for the escitalopram comparison and very low for waitlist. MBSR is a well-tolerated, nonpharmacologic treatment option for adults with GAD. Anxiety reductions were similar to escitalopram, with fewer adverse events; independent replication is needed. MBSR may be a viable option for patients who prefer non-pharmacological management or who cannot tolerate medication. PROSPERO CRD420251140213. What is already known on this topic: Generalized anxiety disorder (GAD) is common and disabling, and pharmacotherapy is frequently discontinued because of adverse effectsPrevious reviews of mindfulness-based interventions for anxiety pooled different programs and diagnoses, with inconsistent findingsRecent noninferiority trials comparing Mindfulness-Based Stress Reduction (MBSR) with escitalopram had not been synthesizedWhat this study adds: MBSR reduced anxiety symptoms compared with waitlist and general active comparators, although certainty of evidence for the waitlist comparison was very lowIn two linked trials, anxiety reductions with MBSR were similar to those with escitalopram (high certainty evidence; g=0.09, 95% CI -0.11 to 0.29), with fewer adverse events in the in-person trial (15% v 79%; number needed to treat to avoid harm 2)Independent replication and head-to-head trials against cognitive behavioral therapy are needed.

PMID 42996257
Read full article →

+8356 more articles available with a free account

Sign up free to view all articles →

Ask about escitalopram + clonazepam